In contrast, in the non-chemotherapy group, the overall survival rate of SLFN11-positive patients was worse (P=0.034), which highlights the “predictive” nature of SLFN11-its benefits are only manifested in the context of chemotherapy, probably because high expression of SLFN11 marks the inherent sensitivity of the tumor to DNA damaging agents, but in the absence of chemotherapy, it is associated with an aggressive phenotype. Here, SLFN11 is linked to neoplasm.